PKD Cures Act

This legislative proposal seeks to significantly advance research and treatment for polycystic kidney disease (PKD), a severe genetic condition impacting approximately 500,000 Americans and leading to end-stage renal disease. The bill highlights the substantial burden of PKD, including its annual cost of $3 billion to Medicare for related kidney failure.

A central provision expands and intensifies National Institutes of Health (NIH) research into PKD, encompassing basic, translational, and clinical studies to understand its mechanisms, identify therapeutic targets, and evaluate treatments. This expansion also mandates collaboration with federal agencies, academic institutions, and private sector stakeholders, alongside supporting training programs for specialized researchers and clinicians.

Furthermore, the bill directs the NIH to establish a working group tasked with developing a comprehensive roadmap for PKD research and innovation. This group, comprising experts and patient advocates, will identify research gaps, recommend collaboration strategies, propose timelines, and integrate new technologies like artificial intelligence and precision medicine into PKD research and care. The working group is required to submit a detailed report, including this roadmap, to Congress within 24 months of the bill's enactment.